Mesenchymal stem cells therapy in children with end-stage kidney disease

report of two cases

  • Eka Laksmi Hidayati FKUI
  • Reza Fahlevi
  • Henny Adriani Puspitasari
  • Anisa Rahmadhany
  • Sudung Oloan Pardede
Keywords: pediatric chronic kidney disease; end-stage kidney disease; stem cells

Abstract

Chronic kidney disease (CKD) is a major health problem worldwide, with increasing incidence and prevalence. While the incidence of CKD in children is relatively low, CKD contributes to major health problems and has many long-term effects.1 Chronic kidney disease is characterized by a gradual decline in kidney function over time. The Kidney Disease Improving Global Outcomes (KDIGO) report defined CKD as an abnormality of renal structure or function with decreased glomerular filtration rate (GFR) that lasts more than three months. Chronic kidney disease is classified into 5 stages based on the GFR value.2

               Patients with stage V CKD transition from progressive disease to irreversible, terminal, end-stage kidney disease (ESKD). To date, the standard of ESKD management has been kidney replacement therapy, consisting of hemodialysis (HD), peritoneal dialysis (PD), and/or kidney transplantation. Complexity and cost of kidney care have obvious consequences on the availability of kidney replacement therapy for children, especially in developing countries. Dialysis provides only partial replacement of renal functions, especially clearance and fluid balance, but does not cure the disease. Kidney transplantation is a curative management, but donor availability for pediatric patients remains challenging

References

1. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clin Kidney J. 2016;9:583-91. DOI: 10.1093/ckj/sfw047.
2. Kidney diseases: improving global outcome (KDIGO). KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int (Suppl). 2013;3:136-50. DOI: 10.7326/0003-4819-158-11-201306040-00007.
3. Huling J, Yoo JJ. Comparing adult renal stem cell identification, characterization and applications. J Biomed Sci. 2017;24:32-43. DOI: 10.1186/s12929-017-0339-7.
4. Wei X, Yang X, Han Z, Qu F, Shao L, Shi Y. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacologica Sin. 2013;34:747-54. DOI: 10.1038/aps.2013.50.
5. Matsumoto T, Schäffers OJM, Yin W, Morizane R. Renal regeneration: stem cell-based therapies to battle kidney disease. EMJ Nephrol. 2019;7:54-64.
6. Rota C, Morigi M, Imberti B. Stem cell therapies in kidney diseases: progress and challenges. Int J Mol Sci. 2019;20:2790-816. DOI: 10.3390/ijms20112790.
7. Papazova, DA, Oosterhuis NR, Gremmels H, van Koppen A, Joles JA, Verhaar MC. Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis. Dis Model Mech. 2015;8:281-93. DOI: 10.1242/dmm.017699.
8. Marcheque J, Bussolati B, Csete M, Perin L. Concise reviews: stem cells and kidney regeneration: an update. Stem Cells Transl Med. 2019;8:82-92. DOI: DOI: 10.1002/sctm.18-0115.
9. Rota C, Morigi M, Cerullo D, Introna M, Colpani O, Corna D, et al. Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. Stem Cell Res Ther. 2018;9:220-34. DOI: 10.1186/s13287-018-0960-8.
10. Yun CW, Lee SH. Potential and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for acute/chronic kidney disease. Int J Mol Sci. 2019;20:1619-35. DOI: 10.3390/ijms20071619.
11. Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16:R79. DOI: 10.1186/ar4520.
12. Ding XF, Liang HY, Yuan B, Li LF, Wang T, Kan QC, et al. Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies. Stem Cell Res Ther. 2019;10:55. DOI: 10.1186/s13287-019-1162-8.
13. Patel NM, Burger CD. Two cases of stem cell therapy for pulmonary hypertension: a clinical report. Respir Med CME. 2011;4:70-4. DOI: 10.1016/j.rmedc.2010.09.002.
14. Belingheri M, Lazzari L, Parazzi V, Groppali E, Biagi E, Gaipa G, et al. Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis. Biologicals. 2013;41:439–45. DOI: 10.1016/j.biologicals.2013.09.004.
Published
2022-06-02
How to Cite
1.
Hidayati E, Fahlevi R, Puspitasari H, Rahmadhany A, Pardede S. Mesenchymal stem cells therapy in children with end-stage kidney disease. PI [Internet]. 2Jun.2022 [cited 12Aug.2022];62(3):217-2. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2810
Section
Pediatric Nephrology
Received 2021-10-13
Accepted 2022-06-02
Published 2022-06-02